<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138008</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG0401</org_study_id>
    <secondary_id>C000000026</secondary_id>
    <nct_id>NCT00138008</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy</brief_title>
  <official_title>Randomized Controlled Trial to Evaluate Radiotherapy Followed by Endocrine Therapy vs. Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy (JCOG0401)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haruhiko Fukuda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in
      comparison with endocrine therapy alone for PSA failure after radical prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled trial is conducted in Japan to evaluate radiotherapy followed by
      endocrine therapy for PSA failure after radical prostatectomy. Patients who have PSA failure
      after radical prostatectomy under a diagnosis of localized prostate cancer (T1-2 N0M0) are
      randomized into treatment group of either radiotherapy followed by endocrine therapy or
      endocrine therapy alone. Urologic Oncology Study Group (UOSG) in the JCOG composed of 36
      specialized institutions will recruit 200 patients. The primary endpoint is time to treatment
      failure (TTF) of bicalutamide and secondary endpoints are TTF of protocol treatment,
      progression free survival, overall survival, adverse events and quality of life (QOL). The
      Clinical Trial Review Committee of the Japan Clinical Oncology Group (JCOG) approved the
      protocol on April 13, 2004, and the study was activated on May 17, 2004.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to treatment failure (TTF) of bicalutamide</measure>
    <time_frame>time to treatment failure (TTF) of bicalutamide</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TTF of protocol treatment</measure>
    <time_frame>TTF of protocol treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical progression free survival</measure>
    <time_frame>time to clinical progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>overall</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>overall</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient-reported quality of life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: endocrine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endocrine therapy</intervention_name>
    <description>Drug: endocrine therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>Procedure/Surgery: radiotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of localized prostate cancer (clinical stage T1-2N0M0) which is treated by
             radical prostatectomy

          -  Pathological stage: pT0/2/3 and pN0/x

          -  Serum level of PSA once reached &lt; 0.1 ng/ml after radical prostatectomy and then
             increased 0.4 ng/ml

          -  Serum level of PSA 1.0 ng/ml at entry

          -  No clinical recurrence based on abdominal and pelvic computed tomography, and a bone
             scan

          -  No history of chemotherapy or radiation therapy or endocrine therapy for any cancer

          -  Ages 20 to 79 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  No blood transfusion within 28 days of entry

          -  Sufficient organ function within 28 days of entry

          -  Provided written informed consent

        Exclusion Criteria:

          -  Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ

          -  Mental disease or mental symptoms which would affect participant's decision to
             participate

          -  Continuous medication with steroids (exclude external use of steroids for skin)

          -  Ischemic heart disease or arrhythmia which needs medical treatment

          -  Poorly controlled hypertension

          -  Poorly controlled diabetes mellitus

          -  History of cerebral infarction or myocardial infarction within 6 months

          -  Liver cirrhosis

          -  Interstitial pneumonia which requires ventilation assistance, oxygen inhalation,
             steroids, or diuretic medicine
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seiji Naito, MD, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Graduate School of Medical Science, Kyushu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya University School of Medicine</name>
      <address>
        <city>Nagoya,Showa-ku,Tsurumai-cho,65</city>
        <state>Aichi</state>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akita University School of Medicine</name>
      <address>
        <city>Akita,Hondo,1-1-1</city>
        <state>Akita</state>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University, Graduate School of Medicine</name>
      <address>
        <city>Chiba,Chuo-ku,Inohana,1-8-1</city>
        <state>Chiba</state>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center Hospital</name>
      <address>
        <city>Chiba,Chuo-ku,Nitona-cho,666-2</city>
        <state>Chiba</state>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama,Horinouchi,13</city>
        <state>Ehime</state>
        <zip>790-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graduate School of Medical Science, Kyushu University</name>
      <address>
        <city>Fukuoka, Higashi-ku,Maidashi,3-1-1</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University School of Medicine</name>
      <address>
        <city>Kurume,Asahi-machi,67</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma University</name>
      <address>
        <city>Maebashi,Showa,3-39-15</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>North-14 West-5 Kita-ku,Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University</name>
      <address>
        <city>S-1,W-16,Chuo-ku,Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Graduate School of Medicine</name>
      <address>
        <city>Kobe,Chuo-ku,Kusunoki-cho,7-5-2</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Medicine,Tsukuba University Hospital</name>
      <address>
        <city>Tsukuba,Tennodai,1-1-1</city>
        <state>Ibaraki</state>
        <zip>305-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Kagawa University</name>
      <address>
        <city>Kita,Miki-cho,Ikenobe,1750-1</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University,Faculty of Medicine</name>
      <address>
        <city>Kagoshima,Sakuragaoka,8-35-1</city>
        <state>Kagoshima</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University School of Medicine</name>
      <address>
        <city>Sagamihara,Kitasato,1-15-1</city>
        <state>Kanagawa</state>
        <zip>228-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto,Sakyo-ku,Syogoinkawara,54</city>
        <state>Kyoto</state>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University School of Medicine</name>
      <address>
        <city>Tsu,Edobashi,2-174</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center</name>
      <address>
        <city>Natori,Medeshima-Shiode,Nodayama,47-1</city>
        <state>Miyagi</state>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai,Aoba-ku,Seiryo-machi,1-1</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinshu University</name>
      <address>
        <city>Matsumoto,Asahi,3-1-1</city>
        <state>Nagano</state>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University</name>
      <address>
        <city>Kashihara,Shijo-cho,840</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical and Dental Hospital</name>
      <address>
        <city>Niigata,Asahimachi-dori,1-754</city>
        <state>Niigata</state>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata,Kawagishi-cho,2-15-3</city>
        <state>Niigata</state>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki,Miwa,1-1-1</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama,Shikata-cho,2-5-1</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka,Higashinari-ku,Nakamichi,1-3-3</city>
        <state>Osaka</state>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimane University Faculty of Medicine</name>
      <address>
        <city>Izumo,Enya-cho,89-1</city>
        <state>Shimane</state>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu,Handayama,1-20-1</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sizuoka Cancer Center</name>
      <address>
        <city>Sunto-gun,Nagaizumi-cho,Shimonagakubo,1007</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi Cancer Center</name>
      <address>
        <city>Utsunomiya,Yohnan,4-9-13</city>
        <state>Tochigi</state>
        <zip>320-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku,Tsukiji,5-1-1</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei University Hospital</name>
      <address>
        <city>Minato-ku,Nishishinbashi,3-25-8</city>
        <state>Tokyo</state>
        <zip>105-8461</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku,Shinanomachi,35</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Faculty of Medicine</name>
      <address>
        <city>Nakakoma,Tamaho,Shimokato,1110</city>
        <state>Yamanashi</state>
        <zip>409-3898</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Japan Clinical Oncology Group</investigator_affiliation>
    <investigator_full_name>Haruhiko Fukuda</investigator_full_name>
    <investigator_title>JCOG Data Center</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>radical prostatectomy</keyword>
  <keyword>PSA failure</keyword>
  <keyword>RCT</keyword>
  <keyword>radiation</keyword>
  <keyword>endocrinotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

